VolitionRX Advances Commercial Strategy with Key Clinical and Market Developments

The diagnostics company VolitionRX has announced a series of strategic updates across its human and veterinary healthcare platforms. These developments span from new clinical data for a chronic skin condition to reimbursement progress in a major European market and expanded commercial availability for its animal cancer tests, all supported by recent capital financing.

In January, VolitionRX secured $2.0 million in funding, providing capital to advance its commercialization efforts. Investors are now looking toward the fourth quarter of 2026, which is the targeted period for the routine launch of its cancer tests in France. Prior to that, initial sales figures from the recent U.S. expansion in the veterinary segment are expected to offer early indicators of commercial traction.

Veterinary Division Gains Momentum with Geographic Expansion

The company's veterinary cancer detection business is experiencing significant geographic growth. As of this month, the Nu.Q® Vet cancer test is being offered comprehensively across all 50 U.S. states, as well as in Taiwan and China. Recent data highlighting the test's accuracy for detecting lymphoma in cats demonstrates its potential, with the liquid biopsy assay showing a sensitivity of over 80% alongside a specificity of 100%.

Should investors sell immediately? Or is it worth buying VolitionRX?

Focus on Inflammatory Disease and Cancer Detection

New data presented at a specialist conference in Malta yesterday highlighted an application for the Nu.Q® NETs assay. Clinical study results indicate the test can classify the severity of the chronic skin disease Hidradenitis Suppurativa (HS), which could assist physicians in making more informed treatment decisions. The assay, which already carries a CE mark, is clinically available in the EU and the United Kingdom. The company estimates the total market potential for applications in the area of NETosis at $3.8 billion.

French Market Access Represents a Major Milestone

A key strategic focus is the French healthcare market. In collaboration with the Hospices Civils de Lyon hospital network, VolitionRX is preparing for the potential reimbursement of its cancer tests by state authorities. Given approximately 50,000 new lung cancer diagnoses annually in France, this represents a significant future growth lever. A decision from the authorities regarding approval and reimbursement is anticipated within the next five months.